Targeted treatments for breast cancer

Thursday 25 May 2017, Christie Hospital Manchester

1-day course: Targeted Treatments for Breast Cancer

Level: Intermediate

Description: This study day will describe many different faulty processes that drive the growth and spread of breast cancer. It will also introduce the science behind a plethora of licensed and yet-to-be licensed breast cancer treatments such as HER2-targeted therapies, PARP inhibitors and CDK inhibitors. To set the scene, the science behind standard treatments such as chemotherapy, radiotherapy and hormone therapy will be explained.

Audience: Ideal for research nurses, clinical nurse specialists, administrative staff, clinical trials coordinators

To book, contact: education.events@christie.nhs.uk or call: 0161 446 3403

Programme:

• Cells, DNA, chromosomes, genes, proteins
• Cell division & the cell cycle
• Causes, types and consequences of DNA damage
• Drivers of treatment resistance: the cancer microenvironment, genomic instability, intra-umoural heterogeneity

• How breast cancer develops
• Faulty genes and proteins that drive breast cancer
• The role of hormone receptors and HER2
• Breast cancer stem cells
• How and why breast cancers spread

• The mechanism of action of chemotherapy and radiotherapy
• The history of hormone therapies for cancer
• Targeting cell communication pathways: monoclonal antibodies and kinase inhibitors

• The current landscape of breast cancer treatments
• Hormone therapies – targeting the oestrogen receptor and aromatase
• HER2-targeted treatments: trastuzumab, pertuzumab, lapatinib & T-DM1
• PI3K/AKT/mTOR pathway inhibitors e.g. everolimus , copanlisib, buparlisib